DEF 14A: STAAR Surgical Aims for Vision 2026 with Focus on ICL Growth and Shareholder Value

STAAR Surgical is focusing on expanding its EVO ICL technology to more patients globally and creating significant shareholder value, despite macroeconomic challenges in 2023.

Summary

• STAAR Surgical Company is focused on disrupting refractive vision correction with Implantable Collamer Lenses (ICLs).
• In 2023, STAAR's net sales grew by 13% to $322.4 million, with ICL sales up 18% compared to 2022.
• The company generated a net income of $21.3 million in 2023 and ended the year with $232.4 million in cash, cash equivalents, and investments available for sale.
• STAAR expects to sell more ICLs in the next three years (2024-2026) than in the first 25 years of ICL sales combined.
• Strategic priorities for 2024 include increasing surgeon confidence, growing sales mix, new product innovation, expanding into new markets, and creating a high-performance organization.
• The company is seeking shareholder approval for an amendment to its equity incentive plan to increase the number of shares available for grant by 2.6 million.
• The Annual Meeting of Shareholders will be held on June 20, 2024, to vote on director elections, the equity incentive plan amendment, ratification of the accounting firm, and executive compensation.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While it highlights positive growth in net sales and ICL sales, it also acknowledges macroeconomic challenges, a decline in refractive industry procedures, and the failure to meet bonus targets. The focus on future growth and strategic initiatives suggests a cautiously optimistic outlook.

Positives

• STAAR Surgical achieved global growth and profitability in 2023.
• The company is investing in consumer awareness of the EVO ICL.
• STAAR has a strong balance sheet to support growth in 2024 and beyond.
• The company is creating a Department of Global Professional Education and Training to enhance knowledge of ICL technology.
• STAAR is investing in its organization and people to create a High-Performance Organization.
• The company received over 95% support from shareholders on its say-on-pay advisory vote at the 2023 Annual Meeting.

Negatives

• The company faced macroeconomic challenges and a global decline in refractive industry procedures in 2023.
• The annual bonus plan was funded at 50% of target due to performance falling short of goals.
• Performance stock units granted to management in 2023 did not vest and were forfeited.

Risks

• Macroeconomic challenges and a global decline in refractive industry procedures could impact future performance.
• Failure to execute on strategic priorities and growth initiatives could hinder the company's ability to bring EVO ICL to more patients.
• Inability to attract, retain and motivate key executives and employees due to limited share reserve.

Future Outlook

STAAR expects to sell more ICLs in the next three years (2024-2026) than the first 25 years of ICL sales combined and focuses on strategic priorities and growth initiatives to bring the EVO ICL to more patients globally and create significant shareholder value.

Management Comments

• At STAAR, our vision is to be the first choice for doctors and patients seeking visual freedom from the hassles of eyeglasses or contact lenses.
• We believe that our lens-based vision correction technology will continue to disrupt traditional laser-based refractive procedures, as more and more surgeons and patients seek out the benefits and advantages of our Implantable Collamer Lenses (ICLs).
• We believe that if we execute on our strategic priorities and growth initiatives, we can bring the EVO ICL to more patients globally and create significant shareholder value.

Industry Context

The document notes a global decline in refractive industry procedures in 2023, suggesting a challenging environment for companies in this sector. STAAR's growth, despite this decline, indicates a potential outperformance relative to its peers.

Comparison to Industry Standards

• The document mentions a peer group of medical device companies with market capitalizations between $900 million and $8.1 billion and revenue generally between $140 million and $840 million.
• The peer group includes companies such as AtriCure, iRhythm Technologies, Axonics, Merit Medical Systems, Cardiovascular Systems, Nevro, Glaukos, NuVasive, Globus Medical, Penumbra, ICU Medical, QuidelOrtho, Inari Medical, ShockWave Medical, Inogen, Tandem Diabetes Care, and Inspire Medical Systems.
• The company's three-year average unadjusted burn rate of 1.6% is mentioned in the context of institutional shareholder advisory firms tests and recommended practices.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The company aims to create significant shareholder value through the growth of EVO ICL.
• Employees: The company is investing in its organization and people to create a High-Performance Organization.
• Customers (Surgeons and Patients): The company is focused on increasing surgeon confidence and providing visual freedom for patients.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the Proxy Statement.
• The company will continue to focus on its strategic priorities and growth initiatives for 2024.
• The company will continue to engage surgeons and their staffs, globally, through clinical validation, education and strategic cooperation.

Key Dates

Keywords

ICL, STAAR Surgical, EVO ICL, Implantable Collamer Lens, Refractive vision correction, Shareholder value, Annual Meeting, Proxy Statement, Executive compensation, Director nominees, Equity incentive plan